Pluri Signs Manufacturing Deal with Kadimastem

• Pluri Inc. signs tech transfer and manufacturing agreement with Kadimastem Ltd.

• PluriCDMO to produce cell therapies for ALS and diabetes treatments.

Pluri Inc., a biotechnology company, has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. The agreement involves PluriCDMO, which was launched earlier this year and leverages Pluri’s 47,000 sq.-ft. GMP cell production facility to manufacture cell-based products for life science companies.

PluriCDMO will manufacture two cell therapy candidates for Kadimastem: AstroRx, clinical grade human astrocytes for the treatment of ALS for an upcoming U.S. FDA Phase 2a study; and IsletRx, clinical grade pancreatic islet cells for the treatment of diabetes. PluriCDMO offers experience in developing and manufacturing cell-based products in GMP grade for clinical use, from initial clinical trial batches to mass scale commercial production.

“Working with Pluri marks a pivotal milestone, enhancing Kadimastem’s capacity to manufacture our products under GMP conditions,” said Ronen Twito, Executive Chairman & President of Kadimastem. “This collaboration is integral to our strategy as we prepare for clinical trials and expand into the US market with our AstroRx product candidate.”

Yaky Yanay, Chief Executive Officer and President of Pluri, added, “We are excited to work with Kadimastem and support their development of cell therapies, potentially improving the lives of patients with ALS and diabetes. This collaboration underscores the versatility of our PluriCDMO platform and our commitment to aiding innovative companies in advancing their life-saving therapies. We look forward to a successful collaboration with Kadimastem as they progress their clinical development programs.”